Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition.
More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html